ISUP 膀胱癌分子病理进展与挑战
2019 年 ISUP 咨询会议膀胱癌工作组基于会前调查,综述膀胱癌分子分型、TERT 启动子突变、FGFR3 突变及 IO 治疗相关标志物,并给出诊断使用推荐。分子分型目前不推荐临床使用;TERT 启动子突变有助于鉴别组织学欺骗性癌与良性 mimics;FGFR3 检测是 erdafitinib 治疗前提;一线 IO 前需 PD-L1 IHC。
要点
- 膀胱癌分子分型与临床行为相关,但目前不推荐临床使用。
- TERT 启动子突变见于多数膀胱癌,可助鉴别良性 mimics。
- FGFR3 突变检测是转移性 UC 使用 erdafitinib 的前提。
核心结论
- 膀胱癌生物学认识已改善患者护理,但分子分型临床效用未证实,不推荐使用。
- TERT 启动子突变分析在某些病例可区分组织学欺骗性癌与良性 mimics。
- 转移性 UC 伴 FGFR3 突变常对 erdafitinib 应答,用药前须检测 FGFR3 改变。
- 一线 IO 治疗前须行 PD-L1 免疫组化;转移性 UC 对 IO 应答率 20%。
研究设计与样本
- 2019 年 ISUP 泌尿生殖系统癌症分子病理咨询会议膀胱癌工作组报告,纳入会前调查。
主要发现
- 膀胱癌可基于表达谱分为分子亚型,与临床行为、组织学及分子改变相关。
- TERT 启动子突变见于多数膀胱癌,包括肿瘤演化的非浸润阶段,不见于反应性病变。
- FGFR3 突变在膀胱癌中常见,伴该突变的转移性 UC 常对 erdafitinib 应答。
- 转移性 UC 对 IO 药物应答率为 20%,TMB、分子亚型及 PD-L1 阳性淋巴细胞浸润与应答相关。
关键数值与推荐
- 目前不推荐膀胱癌分子分型用于临床。
- 使用 erdafitinib 前须检测 FGFR3 改变。
- 一线使用 IO 药物前须行 PD-L1 免疫组化。
- IO 药物已获批用于转移性 UC 一线和二线治疗。
临床怎么用
- 对组织学诊断困难病例可考虑 TERT 启动子突变检测辅助鉴别良恶性。
- 转移性 UC 拟用 erdafitinib 前应检测 FGFR3 突变。
- 一线免疫治疗前应常规行 PD-L1 免疫组化。
局限性
- 分子分型临床效用尚未证实。
- 仅少数病理医生使用 TERT 启动子突变检测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
During the 2019 International Society of Urological Pathology Consultation Conference on Molecular Pathology of Urogenital Cancer, the Working Group on Bladder Cancer presented the current status and made recommendations on the diagnostic use of molecular pathology, incorporating a premeeting survey. Bladder cancers are biologically diverse and can be separated into "molecular subtypes," based on expression profiling. These subtypes associate with clinical behavior, histology, and molecular alterations, though their clinical utility has not been demonstrated at present and use in bladder cancer is not recommended. Mutations in the TERT promoter are present in the majority of bladder cancers, including the noninvasive stage of tumor evolution, but not in reactive conditions. Mutational analysis of the TERT promoter thus distinguishes histologically deceptive cancers from their benign mimics in some cases. A minority of pathologists employ this test. FGFR3 mutations are common in bladder cancer, and metastatic urothelial carcinoma (UC) with such mutations frequently responds to erdafitinib, an FGFR inhibitor. Testing for FGFR3 alterations is required before using this drug. Metastatic UC responds to immune-oncology (IO) agents in 20% of cases. These are approved as first and second-line treatments in metastatic UC. Several biological parameters associate with response to IO agents, including tumor mutational burden, molecular subtype, and infiltration by programmed death-ligand 1-positive lymphocytes, detected by immunohistochemistry. Programmed death-ligand 1 immunohistochemistry is mandatory before administering IO agents in the first-line setting. In conclusion, much has been learned about the biology of bladder cancer, and this understanding has improved the care of patients with the disease.
引用
- Warrick JI, Knowles MA, Yves A, et al. Report From the International Society of Urological Pathology (ISUP) Consultation Conference On Molecular Pathology Of Urogenital Cancers. II. Molecular Pathology of Bladder Cancer: Progress and Challenges. Am J Surg Pathol. 2020. PMID: 32091435. doi:10.1097/PAS.0000000000001453
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。